NCT01682083 2026-04-21
COMBI-AD
Novartis
Phase 3 Completed
Clinical Trials
29 trialsNCT03149029 2026-04-21
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT01979523 2026-04-13
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02224781 2026-02-18
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02967692 2025-09-18
COMBI-i
Novartis
Phase 3 Terminated
NCT03551626 2025-04-29
COMBI-APlus
Novartis
Phase 3 Completed
NCT05260684 2025-03-06
OCEANMIST
Pfizer
Completed
NCT01902173 2025-01-14
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT04310397 2024-10-30
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02097225 2024-10-16
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT03455764 2024-07-31
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT03272464 2023-09-22
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
Massachusetts General Hospital
Phase 1 Terminated
NCT02130466 2022-08-01
MK-3475-022
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT02083354 2022-02-01
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
Novartis
Phase 2 Completed
NCT02974803 2021-08-20
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Canadian Cancer Trials Group
Phase 2 Terminated
NCT02296112 2021-05-28
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT01597908 2021-02-24
COMBI-v
Novartis
Phase 3 Completed
NCT01584648 2021-02-17
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Novartis
Phase 3 Completed
NCT01941927 2020-02-12
Trametinib With GSK2141795 in BRAF Wild-type Melanoma
University of California, San Francisco
Phase 2 Completed
NCT01072175 2019-07-05
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
Novartis
Phase 2 Completed
NCT02039947 2019-05-21
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Novartis
Phase 2 Completed
NCT02314143 2019-02-18
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
GlaxoSmithKline
Phase 2 Terminated
NCT01978236 2018-08-17
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
GlaxoSmithKline
Phase 2 Terminated
NCT01245062 2018-04-05
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
GlaxoSmithKline
Phase 3 Completed
NCT01721603 2018-01-23
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets
University of California, San Francisco
Phase 2 Terminated
NCT01928940 2017-07-24
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
GlaxoSmithKline
Phase 2 Completed
NCT01701037 2017-06-23
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT01619774 2016-12-12
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01037127 2014-03-31
Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor
GlaxoSmithKline
Phase 2 Completed